NuCana plc
NASDAQ: NCNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hugh Stephen Griffith
- Employees
- 20
- Headquarters
- Edinburgh, United Kingdom
- IPO year
- 2017
- Market cap
- $10.0M
- Website
- https://www.nucana.com
Loading NCNA…
Loading profile data…Frequently asked questions about NCNA
What does NuCana plc (NCNA) do?
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase...
Where does NCNA trade?
NuCana plc (NCNA) trades on the NASDAQ Global Select.
What sector is NCNA in?
NuCana plc (NCNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NuCana plc?
Hugh Stephen Griffith is the chief executive officer of NuCana plc (NCNA).
Where is NuCana plc headquartered?
NuCana plc is headquartered in United Kingdom.
Does NCNA pay a dividend?
NuCana plc (NCNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NCNA go public?
NuCana plc (NCNA) completed its initial public offering in 2017.
Is NCNA an ADR?
Yes — NCNA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. NuCana plc reporting and dividends follow the underlying issuer.